Clinical trials: Opiate Substitution Treatment, active
Smoking Cessation, Substance-Related Disorders
Easy Access to Smoking Cessation for People Receiving Opioid Agonist Therapy Who Are Smoking Tobacco
Background: About 85% of those receiving opioid agonist therapy (OAT) for opioid dependence are smoking tobacco. Cigarette smoke lead to lunge diseases and cause illness and death within this group.
- Trial name
- BAReNikotin (NCT05290025)
- Testing
- Nicotine patch, Nicotine gum, Nicotine lozenge
- Where
- 2 sites in Norway
- Volunteers
- 266 people
- Sponsor
- Haukeland University Hospital
Chronic Pain, Tobacco Use
Opioids, Low Nicotine Cigarettes, and Chronic Pain
The purpose of this study is to evaluate the effects of switching to very low nicotine content (VLNC) cigarettes versus normal nicotine content (NNC) cigarettes on craving, withdrawal, and pain among individuals with chronic pain…
- Conditions
- Chronic Pain, Tobacco Use, Opioid Substitution Treatment
- Trial name
- NCT06747871
- Testing
- Very Low Nicotine Cigarettes (VLNC), Normal Nicotine Cigarettes (NNC)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Opioid-Related Disorders, Mobile Applications
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
The proposed clinical trial would evaluate the use of smartphone applications ("apps", which have well-established efficacy in reducing cigarette and alcohol use) to prevent relapse among patients receiving medication-assisted…
- Conditions
- Opioid-Related Disorders, Mobile Applications, Opiate Substitution Treatment, Magnetic Resonance Imaging
- Trial name
- NCT05336188
- Testing
- Smartphone
- Where
- United States
- Volunteers
- 336 people
- Sponsor
- University of Arkansas
Neonatal Abstinence Syndrome
The Alberta Neonatal Abstinence Syndrome Mother-Baby Care ImprovEmeNT Program
Neonatal Abstinence Syndrome (NAS), is a common and costly problem in Alberta that affects approximately 250 babies per year exposed to drugs during pregnancy. Unfortunately, this has become more common in the last 10 years.
- Trial name
- NASCENT (NCT05226624)
- Testing
- Rooming-in care, Baseline standard of care
- Where
- Canada
- Volunteers
- 240 people
- Sponsor
- University of Alberta
Opioid-Related Disorders, Hepatitis C (HCV)
Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk
This study will test the effectiveness, implementation outcomes, and cost effectiveness of a locally-tailored, health kiosk to reduce overdose, hepatitis C, and HIV risk behavior and improve linkage to care in rural Appalachia.
- Conditions
- Opioid-Related Disorders, Hepatitis C (HCV), Human Immunodeficiency Virus (HIV), Drug Overdose
- Trial name
- NCT05657106
- Testing
- Health kiosk
- Where
- United States
- Volunteers
- 752 people, healthy volunteers welcome
- Sponsor
- April M Young
Chronic Pain, Post-traumatic Stress Disorder
The Norwegian Addiction, Pain and Trauma Study
In populations with substance use disorders (SUD), there is a high prevalence of chronic pain with various underlying causes. Chronic pain can complicate the treatment of SUD and lead to poorer treatment outcomes.
- Conditions
- Chronic Pain, Post-traumatic Stress Disorder, Substance Use Disorders
- Trial name
- NOR-APT (NCT04908410)
- Where
- 4 sites in Norway
- Volunteers
- 1,650 people
- Sponsor
- University Hospital, Akershus
HIV - Human Immunodeficiency Virus
HIV Prevention With PrEP Among People on Opioid Replacement Therapy
The purpose of this study is to assess the feasibility and acceptability of providing oral pre-exposure prophylaxis (PrEP) and opioid agonist therapy (OAT) simultaneously in existing pharmacy-based programs operating in Alberta…
- Trial name
- OAT-PrEP (NCT07160075)
- Testing
- Simultaneous administration of OAT and oral PrEP at existing pharmacy-based programs
- Where
- 6 sites in Canada
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Cara Spence
Asperger's Disorder, Asperger Disorder
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
BRIEF SUMMARY A. "What is the purpose of this study?" BACKGROUND. The QAIAx clinical trial (Quantum SI/SGI Public Health Agency), known operationally as the "AI City Hall Project," represents a landmark intergovernmental research…
- Conditions
- Asperger's Disorder, Asperger Disorder, Autism Disorder, Autism
- Trial name
- QAIAx (NCT07661823)
- Testing
- AI City Hall Project (AIhealth4u - Public Health Central), AI City Hall Project (QAIAx Microcity A - AI Public Health Central)
- Where
- United States
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Veterans Recovery Network Inc.